Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
Sign Up to like & getrecommendations! Published in 2020 at "Zeitschrift fur Gastroenterologie"
DOI: 10.1055/a-1190-5681
Abstract: In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy, and these drugs have already become essential for the treatment of various noncurable tumors. However, monotherapy in advanced hepatocellular carcinoma (aHCC) failed… read more here.
Keywords: combination; response advanced; therapy despite; therapy ... See more keywords
Response of advanced soft tissue sarcoma to apatinib: A retrospective analysis.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e22502
Abstract: e22502Background: Soft tissue sarcomas (STSs) are rare but malignant tumors with high risks of local recurrence and distant metastasis. Promising efficacy of apatinib was reported in several subtyp... read more here.
Keywords: sarcoma apatinib; tissue sarcoma; advanced soft; soft tissue ... See more keywords
Treatment duration and response of advanced renal cell carcinoma (aRCC) patients (pts) who have completed first-line (1L) treatment (tx): Results from a cross-sectional real-world study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.643
Abstract: 643Background: In 2019, there was an estimated 73,820 new cases of kidney cancers in the US. The tx landscape for aRCC is changing rapidly. Recently approved txs for 1L aRCC include new targeted ag... read more here.
Keywords: renal cell; duration response; treatment; response advanced ... See more keywords